{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T21:05:37Z","timestamp":1694639137658},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,7,10]],"date-time":"2010-07-10T00:00:00Z","timestamp":1278720000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s11934-010-0134-4","type":"journal-article","created":{"date-parts":[[2010,7,9]],"date-time":"2010-07-09T09:36:16Z","timestamp":1278668176000},"page":"353-359","source":"Crossref","is-referenced-by-count":8,"title":["The Use of Botulinum Toxin A in Idiopathic Overactive Bladder Syndrome"],"prefix":"10.1007","volume":"11","author":[{"given":"Christopher S.","family":"Gomez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashanth","family":"Kanagarajah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Gousse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,7,10]]},"reference":[{"key":"134_CR1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M, et al.: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002, 21:167\u2013178.","journal-title":"Neurourol Urodyn"},{"key":"134_CR2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW, et al.: Prevalence and burden of overactive bladder in the United States. World J Urol 2003, 20:327\u2013336.","journal-title":"World J Urol"},{"key":"134_CR3","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.urology.2009.06.096","volume":"75","author":"ML Ganz","year":"2010","unstructured":"Ganz ML, Smalarz AM, Krupski TL, et al.: Economic costs of overactive bladder in the United States. Urology 2010, 75:526\u2013532, 532.e1\u2013532.e18.","journal-title":"Urology"},{"key":"134_CR4","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1464-410X.2009.08777.x","volume":"104","author":"C Chapple","year":"2009","unstructured":"\u2022 Chapple C, De Ridder D: The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice? BJU Int 2009, 104:1188\u20131190. This article discusses the roles of various treatment options for overactive bladder.","journal-title":"BJU Int"},{"key":"134_CR5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","volume":"54","author":"CR Chapple","year":"2008","unstructured":"\u2022 Chapple CR, Khullar V, Gabriel Z, et al.: The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008, 54:543\u2013562. This article is an extensive meta-analysis on the efficacy of current antimuscarinics available to treat overactive bladder.","journal-title":"Eur Urol"},{"key":"134_CR6","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.eururo.2008.09.003","volume":"55","author":"G Novara","year":"2009","unstructured":"Novara G: Botulinum neurotoxin type A: the poison that can treat the sick. Eur Urol 2009, 55:560\u2013562.","journal-title":"Eur Urol"},{"key":"134_CR7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00702-007-0728-2","volume":"115","author":"FJ Erbguth","year":"2008","unstructured":"Erbguth FJ: From poison to remedy: the chequered history of botulinum toxin. J Neural Transm 2008, 115: 559\u2013565.","journal-title":"J Neural Transm"},{"key":"134_CR8","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.urology.2003.12.007","volume":"63","author":"HC Kuo","year":"2004","unstructured":"Kuo HC: Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004, 63:868\u2013872.","journal-title":"Urology"},{"key":"134_CR9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.juro.2008.03.028","volume":"180","author":"L Brubaker","year":"2008","unstructured":"\u2022 Brubaker L, Richter HE, Visco A, et al.: Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008, 180:217\u2013222. This randomized placebo controlled study was conducted to evaluate the efficacy of botulinum toxin A in OAB-wet patients.","journal-title":"J Urol"},{"key":"134_CR10","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.juro.2006.10.050","volume":"177","author":"BL Cohen","year":"2007","unstructured":"\u2022 Cohen BL, Rivera R, Barboglio P, Gousse A: Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection. J Urol 2007, 177:1006\u20131010. This article discusses the safe use of flexible cystoscopy for injecting botulinum toxin A.","journal-title":"J Urol"},{"key":"134_CR11","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","volume":"181","author":"MK Flynn","year":"2009","unstructured":"\u2022 Flynn MK, Amundsen CL, Perevich M, et al.: Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 2009, 181:2608\u20132615. This randomized controlled trial evaluated the use of botulinum toxin A.","journal-title":"J Urol"},{"key":"134_CR12","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.juro.2007.01.130","volume":"177","author":"A Sahai","year":"2007","unstructured":"Sahai A, Khan MS, Dasgupta P: Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007, 177:2231\u20132236.","journal-title":"J Urol"},{"key":"134_CR13","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.juro.2008.11.110","volume":"181","author":"S Khan","year":"2009","unstructured":"\u2022 Khan S, Kessler TM, Apostolidis A, et al.: What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection. J Urol 2009, 181:1773\u20131778. This initial report details the effect of repeat injections of botulinum toxin A.","journal-title":"J Urol"},{"key":"134_CR14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-5347(06)00590-8","volume":"176","author":"DM Schmid","year":"2006","unstructured":"Schmid DM, Sauermann P, Werner M, et al.: Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006, 176:177\u2013185.","journal-title":"J Urol"},{"key":"134_CR15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00192-007-0548-9","volume":"19","author":"S Kuschel","year":"2008","unstructured":"Kuschel S, Werner M, Schmid DM, et al.: Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up. Int Urogynecol J Pelvic Floor Dysfunct 2008, 19:905\u2013909.","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"134_CR16","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.juro.2007.05.136","volume":"178","author":"HC Kuo","year":"2007","unstructured":"Kuo HC: Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 2007, 178:1359\u20131363.","journal-title":"J Urol"},{"key":"134_CR17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.urology.2009.05.097","volume":"75","author":"A Sahai","year":"2010","unstructured":"\u2022 Sahai A, Dowson C, Khan MS, et al.: Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 2010, 75:552\u2013558. This is a report on dose optimization to improve voiding dysfunction after botulinum toxin A injection.","journal-title":"Urology"},{"key":"134_CR18","doi-asserted-by":"crossref","unstructured":"Chancellor MB: Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery. Int Urol Nephrol 2009 July 2 (Epub ahead of print).","DOI":"10.1007\/s11255-009-9600-7"},{"key":"134_CR19","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.juro.2009.06.023","volume":"182","author":"A Giannantoni","year":"2009","unstructured":"Giannantoni A, Rossi A, Mearini E, et al.: Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson\u2019s disease and multiple system atrophy. J Urol 2009, 182:1453\u20131457.","journal-title":"J Urol"},{"key":"134_CR20","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1464-410X.2009.08402.x","volume":"103","author":"A Sahai","year":"2009","unstructured":"Sahai A, Dowson C, Khan MS, Dasgupta P: Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 2009, 103:1509\u20131515.","journal-title":"BJU Int"},{"key":"134_CR21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/nau.20611","volume":"28","author":"BL Cohen","year":"2009","unstructured":"\u2022 Cohen BL, Barboglio P, Rodriguez D, Gousse AE: Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn 2009, 28:205\u2013208. This initial report evaluates the optimal dose of botulinum toxin A for injection in patients with overactive bladder.","journal-title":"Neurourol Urodyn"},{"key":"134_CR22","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1464-410X.2007.07186.x","volume":"100","author":"S Jeffery","year":"2007","unstructured":"Jeffery S, Fynes M, Lee F, et al.: Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 2007, 100:1302\u20131306.","journal-title":"BJU Int"},{"key":"134_CR23","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/01.ju.0000169480.43557.31","volume":"174","author":"R Popat","year":"2005","unstructured":"Popat R, Apostolidis A, Kalsi V, et al.: A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005, 174:984\u2013989.","journal-title":"J Urol"},{"key":"134_CR24","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4103\/0970-1591.40612","volume":"24","author":"NK Mohanty","year":"2008","unstructured":"Mohanty NK, Nayak RL, Alam M, Arora RP: Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: Single center experience. Indian J Urol 2008, 24:182\u2013185.","journal-title":"Indian J Urol"},{"key":"134_CR25","doi-asserted-by":"crossref","unstructured":"Khan S, Panicker J, Roosen A, et al.: Complete Continence after Botulinum Neurotoxin Type A Injections for Refractory Idiopathic Detrusor Overactivity Incontinence: Patient-Reported Outcome at 4\u00a0Weeks. Eur Urol 2009 April 21 (Epub ahead of print).","DOI":"10.1016\/j.eururo.2009.04.020"},{"key":"134_CR26","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eururo.2005.12.012","volume":"49","author":"V Kalsi","year":"2006","unstructured":"Kalsi V, Apostolidis A, Popat R, et al.: Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006, 49:528\u2013535.","journal-title":"Eur Urol"},{"key":"134_CR27","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.clinthera.2007.04.015","volume":"29","author":"SA Yablon","year":"2007","unstructured":"Yablon SA, Brashear A, Gordon MF, et al.: Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther 2007, 29:683\u2013690.","journal-title":"Clin Ther"},{"key":"134_CR28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00404-010-1407-3","volume":"282","author":"K Ashok","year":"2010","unstructured":"Ashok K, Wang A: Detrusor overactivity: an overview. Arch Gynecol Obstet 2010, 282:33\u201341.","journal-title":"Arch Gynecol Obstet"},{"key":"134_CR29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/nau.10099","volume":"22","author":"GA Digesu","year":"2003","unstructured":"Digesu GA, Khullar V, Cardozo L, Salvatore S: Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 2003, 22:105\u2013108. (Published erratum appears in Neurourol Urodyn 2003, 22:356.)","journal-title":"Neurourol Urodyn"},{"key":"134_CR30","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/nau.20821","volume":"29","author":"F Dokmeci","year":"2010","unstructured":"Dokmeci F, Seval M, Gok H: Comparison of ambulatory versus conventional urodynamics in females with urinary incontinence. Neurourol Urodyn 2010, 29:518\u2013521.","journal-title":"Neurourol Urodyn"},{"key":"134_CR31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/nau.20707","volume":"28","author":"AE Gousse","year":"2009","unstructured":"Gousse AE, Gomez CS, Kanagarajah P, et al.: Botox for idiopathic overactive bladder patients refractory to antimuscarinic therapy in the absence of urodynamically demonstrable detrusor overactivity. Neurourol Urodyn 2009, 28:107.","journal-title":"Neurourol Urodyn"},{"key":"134_CR32","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.urology.2007.11.039","volume":"71","author":"A Sahai","year":"2008","unstructured":"Sahai A, Khan MS, Le Gall N, et al.: Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder. Urology 2008, 71:455\u2013459.","journal-title":"Urology"},{"key":"134_CR33","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/AOG.0b013e3181a1f5ea","volume":"113","author":"TM Kessler","year":"2009","unstructured":"Kessler TM, Khan S, Panicker J, et al.: Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol 2009, 113:1046\u20131051.","journal-title":"Obstet Gynecol"},{"key":"134_CR34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.sc.3101736","volume":"43","author":"K Laet De","year":"2005","unstructured":"De Laet K, Wyndaele JJ: Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord 2005, 43:397\u2013399.","journal-title":"Spinal Cord"},{"key":"134_CR35","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1464-410X.2006.06091.x","volume":"97","author":"A Ruffion","year":"2006","unstructured":"Ruffion A, Capelle O, Paparel P, et al.: What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 2006, 97:1030\u20131034.","journal-title":"BJU Int"},{"key":"134_CR36","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.amjoto.2006.09.002","volume":"28","author":"RT Adelson","year":"2007","unstructured":"Adelson RT: Botulinum neurotoxins: fundamentals for the facial plastic surgeon. Am J Otolaryngol 2007, 28:260\u2013266.","journal-title":"Am J Otolaryngol"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-010-0134-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-010-0134-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-010-0134-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T04:18:38Z","timestamp":1635653918000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-010-0134-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,10]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["134"],"URL":"https:\/\/doi.org\/10.1007\/s11934-010-0134-4","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,10]]}}}